- Home
- STIM vs TLSI Comparison
STIM vs TLSI Comparison
Compare STIM & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STIM
- TLSI
- Stock Information
- Founded
- STIM 2003
- TLSI 2010
- Country
- STIM United States
- TLSI United States
- Employees
- STIM N/A
- TLSI N/A
- Industry
- STIM Medical/Dental Instruments
- TLSI Medical Specialities
- Sector
- STIM Health Care
- TLSI Health Care
- Exchange
- STIM Nasdaq
- TLSI Nasdaq
- Market Cap
- STIM 232.3M
- TLSI 204.0M
- IPO Year
- STIM 2018
- TLSI N/A
- Fundamental
- Price
- STIM $3.46
- TLSI $5.54
- Analyst Decision
- STIM Buy
- TLSI Strong Buy
- Analyst Count
- STIM 4
- TLSI 5
- Target Price
- STIM $6.00
- TLSI $10.90
- AVG Volume (30 Days)
- STIM 503.9K
- TLSI 39.7K
- Earning Date
- STIM 08-11-2025
- TLSI 08-13-2025
- Dividend Yield
- STIM N/A
- TLSI N/A
- EPS Growth
- STIM N/A
- TLSI N/A
- EPS
- STIM N/A
- TLSI N/A
- Revenue
- STIM $89,448,000.00
- TLSI $32,141,000.00
- Revenue This Year
- STIM $104.65
- TLSI $55.52
- Revenue Next Year
- STIM $10.69
- TLSI $54.76
- P/E Ratio
- STIM N/A
- TLSI N/A
- Revenue Growth
- STIM 22.16
- TLSI 46.20
- 52 Week Low
- STIM $0.52
- TLSI $3.50
- 52 Week High
- STIM $5.92
- TLSI $6.08
- Technical
- Relative Strength Index (RSI)
- STIM 32.40
- TLSI 53.07
- Support Level
- STIM $3.35
- TLSI $5.18
- Resistance Level
- STIM $3.90
- TLSI $5.54
- Average True Range (ATR)
- STIM 0.18
- TLSI 0.32
- MACD
- STIM -0.03
- TLSI 0.01
- Stochastic Oscillator
- STIM 17.63
- TLSI 82.81
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.